Loading clinical trials...
Loading clinical trials...
An Open-label, Phase I, Dose-escalation Study to Characterize the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose of BAY 2010112, Given Once Daily by Subcutaneous Administration or by Continuous Intravenous Infusion, in Subjects With Castration-resistant Prostate Cancer
Conditions
Interventions
BAY2010112
BAY2010112
Locations
5
Austria
Linz, Upper Austria, Austria
Vienna, Austria
Heidelberg, Baden-Wurttemberg, Germany
Würzburg, Bavaria, Germany
Berlin, Germany
Start Date
November 2, 2012
Primary Completion Date
July 18, 2018
Completion Date
September 26, 2018
Last Updated
September 27, 2019
NCT07225946
NCT04868604
NCT00756665
NCT05743621
NCT04104776
NCT06242119
Lead Sponsor
Bayer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions